VEGFA and neoplasm: N2 type can promote the progression of tumors by expressing vascular endothelial growth factor and a variety of chemokines (CCL2, CCL5, etc.), can inhibit the anti-tumor activity of other immune cells, and can form cell clusters with circulating tumor cells (22–24).